Nexalin Technology commences sales of Gen-2 neurostimulation device
The Fly

Nexalin Technology commences sales of Gen-2 neurostimulation device

Nexalin Technology has commenced sales of its second generation 15 milliamp neurostimulation device into a new mental health center in Oman, dedicated to the use of Nexalin’s neurostimulation device for the treatment of patients with substance abuse disorder. The new clinic opened and commenced treatment of patients with Nexalin’s Gen-2 neurostimulation device following a successful evaluation and inspection of the facility by the Sultanate of Oman’s Ministry of Health, which ensures strict quality standards and adherence to established and robust guidelines and regulations. As previously announced, Nexalin was recently granted regulatory approval for its Gen-2, 15 milliamp neurostimulation device by the Sultanate of Oman’s Ministry of Health.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on NXL:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App